Critical reappraisal of prognostic indicators for 949 mucinous appendiceal neoplasm patients.
HIPEC
cancer differentiation
mitomycin C
peritoneal cancer index
peritonectomy
positive lymph nodes
prior surgical score
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
16 May 2024
16 May 2024
Historique:
revised:
08
04
2024
received:
20
02
2024
accepted:
05
05
2024
medline:
16
5
2024
pubmed:
16
5
2024
entrez:
16
5
2024
Statut:
aheadofprint
Résumé
The standard of care for treatment of an appendiceal mucinous neoplasm with peritoneal dissemination is cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). These two treatments are combined in the operating room. A crucial requirement for benefit long-term is proper patient selection. Clinical and histopathologic prognostic indicators are used, along with the patient's fitness for surgery, to select patients to receive CRS and HIPEC. This study seeks to identify the reliable prognostic indicators for four different groups of patients. They are (1) the low-grade appendiceal mucinous neoplasms (LAMN) with a complete CRS, (2) the mucinous appendiceal adenocarcinomas (MACA) with complete CRS, (3) MACA with lymph node metastases (MACA-LN) with complete CRS, and (4) all histologic subtypes with incomplete cytoreduction. The prognostic indicators were evaluated for their impact on overall survival in these four groups of patients. The completeness of cytoreduction (CC) score statistically significantly showed survival differences in all three histologic subtypes. The peritoneal cancer index (PCI) showed significance with LAMN and MACA-LN but not with MACA and not with incomplete CRS. The prior surgical score (PSS) was a prognostic indicator that predicted the outcome with LAMN, MACA-LN, and incomplete CRS patients but not with the MACA group. Patients who were symptomatic or who had extensive systemic chemotherapy before CRS had a significantly reduced survival. The utility of prognostic indicators varied greatly within our four different groups of appendiceal mucinous neoplasms. CC score was always a reliable prognosticator. Surprisingly, PCI was not.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
The standard of care for treatment of an appendiceal mucinous neoplasm with peritoneal dissemination is cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). These two treatments are combined in the operating room. A crucial requirement for benefit long-term is proper patient selection. Clinical and histopathologic prognostic indicators are used, along with the patient's fitness for surgery, to select patients to receive CRS and HIPEC.
METHODS
METHODS
This study seeks to identify the reliable prognostic indicators for four different groups of patients. They are (1) the low-grade appendiceal mucinous neoplasms (LAMN) with a complete CRS, (2) the mucinous appendiceal adenocarcinomas (MACA) with complete CRS, (3) MACA with lymph node metastases (MACA-LN) with complete CRS, and (4) all histologic subtypes with incomplete cytoreduction. The prognostic indicators were evaluated for their impact on overall survival in these four groups of patients.
RESULTS
RESULTS
The completeness of cytoreduction (CC) score statistically significantly showed survival differences in all three histologic subtypes. The peritoneal cancer index (PCI) showed significance with LAMN and MACA-LN but not with MACA and not with incomplete CRS. The prior surgical score (PSS) was a prognostic indicator that predicted the outcome with LAMN, MACA-LN, and incomplete CRS patients but not with the MACA group. Patients who were symptomatic or who had extensive systemic chemotherapy before CRS had a significantly reduced survival.
CONCLUSION
CONCLUSIONS
The utility of prognostic indicators varied greatly within our four different groups of appendiceal mucinous neoplasms. CC score was always a reliable prognosticator. Surprisingly, PCI was not.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Foundation for Applied Research in Gastrointestinal Oncology
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15(1):49‐58.
Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221(2):124‐132.
Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29‐42.
Sugarbaker PH, van der Speeten K. An overview of peritonectomy, visceral resection, and therapeutic laparoscopy for peritoneal surface malignancy. In: Sugarbaker PH, ed. Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas. 2nd ed. Cine‐Med Publishing; 2017:17‐46.
Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “Pseudomyxoma peritonei”. Am J Surg Pathol. 1995;19(12):1390‐1408.
Misdraji J, Yantiss RK, Graeme‐Cook FM, Balis UJ, Young RH. Appendiceal mucinous neoplasms. A clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27(8):1089‐1103.
Sugarbaker PH, Chang D, Liang JJ. Similar survival among all subtypes of mucinous appendiceal adenocarcinoma except the intermediate subtype, which shows an improved survival. Ann Surg Oncol. 2023;30(3):1874‐1885.
Valasek MA, Pai RK. An update on the diagnosis, grading, and staging of appendiceal mucinous neoplasms. Adv Anat Pathol. 2018;25:38‐60.
Yan H, Pestieau SR, Shmookler BM, Sugarbaker PH. Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second‐look operation. Mod Pathol. 2001;14(3):164‐171.
Sugarbaker PH, Chang D. Lymph node positive pseudomyxoma peritonei. Eur J Surg Oncol. 2022;48(12):2369‐2377.
Van der Speeten K, Stuart OA, Sugarbaker PH. Cancer chemotherapy for peritoneal metastases. Pharmacology and treatment. In: Sugarbaker PH, ed. Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas. 2nd ed. Cine‐Med Publishing; 2017:47‐82.
Sugarbaker PH, Averbach AM, Jacquet P, Stephens AD, Stuart OA. A simplified approach to hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) using a self retaining retractor. In: Sugarbaker PH, ed. Peritoneal Carcinomatosis: Principles of Management. Kluwer; 1996:415‐421.
Berger Y, Jacoby H, Kaufmann MI, et al. Correlation between intraoperative and pathological findings for patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2019;26:1103‐1109.
Bhatt A, Yonemura Y, Mehta S, et al. The Pathologic Peritoneal Cancer Index (PCI) strongly differs from the surgical PCI in peritoneal metastases arising from various primary tumors. Ann Surg Oncol. 2020;27:2985‐2996.
Ghabra S, Chang D, Sugarbaker PH. Prognostic indicators for colorectal peritoneal metastases are different for patients with complete versus incomplete cytoreductive surgery. J Surg Oncol. 2023;128(5):860‐868.
Guaglio M, Baratti D, Kusamura S, et al. Impact of previous gynecologic surgical procedures on outcomes of non‐gynecologic peritoneal malignancies mimicking ovarian cancer: less is more? Ann Surg Oncol. 2021;28:2899‐2908.
Paul BK, Ihemelandu C, Sugarbaker PH. Prior surgical score. An analysis of the prognostic significance of an initial nondefinitive surgical intervention in patients with peritoneal carcinomatosis of a colorectal origin undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy. Dis Colon Rectum. 2018;61(3):347‐354.
Sugarbaker PH, Chang D. Treatment of advanced pseudomyxoma peritonei using cytoreductive surgery including total gastrectomy and perioperative chemotherapy. J Surg Oncol. 2021;124(3):378‐389.
Al dybiat I, Mirshahi S, Belalou M, et al. Injured tissues favor cancer cell implantation via fibrin deposits on scar zones. Neoplasia. 2020;22:809‐819.
Ceelen W, Ramsay RG, Narasimhan V, Heriot AG, De Wever O. Targeting the tumor microenvironment in colorectal peritoneal metastases. Trends Cancer. 2020;6(3):236‐246.
Jacquet P, Sugarbaker PH. Abdominal adhesions causing intestinal obstruction following cytoreductive surgery and early postoperative intraperitoneal chemotherapy. Eur Surg. 1995;27:92‐95.
Klausner JM. The effects of perioperative fluorouracil administration on convalescence and wound healing. Arch Surg. 1986;121:239‐242.
Pestieau SR, Marchettini P, Stuart OA, Chang D, Sugarbaker PH. Prevention of intraperitoneal adhesions by intraperitoneal lavage and intraperitoneal 5‐fluorouracil: experimental studies. Int Surg. 2002;87:195‐200.
Sugarbaker PH, Chang D. Use of early postoperative intraperitoneal 5‐fluorouracil with index cytoreduction improves survival with secondary cytoreductive surgery. J Surg Oncol. 2024;129(2):349‐357.
Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer. A multi‐institutional study. J Clin Oncol. 2004;22(16):3284‐3292.
Mangieri CW, Moaven O, Valenzuela CD, et al. Utility of neoadjuvant chemotherapy for peritoneal carcinomatosis secondary to high‐grade appendiceal neoplasms for patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2022;29:2641‐2648.